Menu
 
Research menu
Jump to menu

Publications:  Prof Peter Schmid

Schmid P, Dent R, O'Shaughnessy J(2020). Pembrolizumab for Early Triple-Negative Breast Cancer. Reply. The New England journal of medicine vol. 382, (26)
10.1056/NEJMc2006684
Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al.(2020). Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Annals of Oncology vol. 31, (5) 582-589.
10.1016/j.annonc.2020.02.003
Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T et al.(2020). Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology vol. 31, (5) 569-581.
10.1016/j.annonc.2020.01.072
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al.(2020). TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. Future Oncology vol. 16, (12) 705-712.
10.2217/fon-2020-0163
Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S et al.(2020). Enhancing global access to cancer medicines. CA Cancer Journal for Clinicians vol. 70, (2) 105-124.
10.3322/caac.21597
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH et al.(2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine vol. 382, (9) 810-821.
10.1056/NEJMoa1910549
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al.(2020). Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. Journal of Clinical Oncology vol. 38, (5) 423-433.
10.1200/JCO.19.00368
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V et al.(2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology vol. 21, (1) 44-59.
10.1016/S1470-2045(19)30689-8
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al.(2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncology vol. 5, (11) 1556-1563.
10.1001/jamaoncol.2019.2526
Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM et al.(2019). IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology vol. 15, (17) 1951-1961.
10.2217/fon-2019-0059
Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tani¿ M et al.(2019). Neoantigen-directed immune escape in lung cancer evolution. Nature vol. 567, (7749) 479-485.
10.1038/s41586-019-1032-7
Schmid P, Chui SY, Emens LA(2019). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. The New England journal of medicine vol. 380, (10) 987-988.
10.1056/NEJMc1900150
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al.(2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology vol. 30, (3) 397-404.
10.1093/annonc/mdy517
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al.(2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology vol. 30, (3) 405-411.
10.1093/annonc/mdy518
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R et al.(2019). Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncology vol. 5, (1) 74-82.
10.1001/jamaoncol.2018.4224
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al.(2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine vol. 379, (22) 2108-2121.
10.1056/NEJMoa1809615
Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ et al.(2018). FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC. Journal of Thoracic Oncology vol. 13, (11) 1733-1742.
10.1016/j.jtho.2018.05.004
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I et al.(2018). Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America vol. 115, (43) E10119-E10126.
10.1073/pnas.1802166115
Schmid P(2018). ESMO 2018 presidential symposium - IMpassion130: Atezolizumab+nab-paclitaxel in triple-negative breast cancer. ESMO Open vol. 3, (6)
10.1136/esmoopen-2018-000453
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al.(2018). IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Annals of oncology : official journal of the European Society for Medical Oncology vol. 29, viii707-viii708.
10.1093/annonc/mdy424.008
Chau I, Haag GM, Rahma OE, Macarulla TM, McCune SL, Yardley DA, Solomon BJ, Johnson M et al. (2018). MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29, viii439-viii440.
10.1093/annonc/mdy288.110
Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al.(2018). Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open vol. 2, (4) 162-174.
10.1002/bjs5.53
Schmid PJ, Garciá-Gutierrez A, Jiménez J (2018). Description and detection of burst events in turbulent flows. Journal of Physics: Conference Series. vol. 1001,
10.1088/1742-6596/1001/1/012015
Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH et al.(2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell vol. 33, (4) 649-663.e4.
10.1016/j.ccell.2018.02.010
Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A et al.(2018). Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Medicine vol. 19, (4) 252-260.
10.1111/hiv.12573
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE et al.(2018). Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet Oncology vol. 19, (4) 521-536.
10.1016/S1470-2045(18)30144-X
Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y et al.(2018). PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. Cell Reports vol. 22, (9) 2469-2481.
10.1016/j.celrep.2018.02.028
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56422
Nathan MR, Schmid P(2018). The emerging world of breast cancer immunotherapy. Breast vol. 37, 200-206.
10.1016/j.breast.2017.05.013
Shepherd L, Borges H, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al.(2018). The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. HIV Medicine vol. 19, (2) 90-101.
10.1111/hiv.12546
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P et al.(2018). Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. Journal of Clinical Oncology vol. 36, (9) 884-890.
10.1200/JCO.2016.71.3495
O'Leary K, Shia A, Schmid P(2017). Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. Curr Cancer Drug Targets vol. 18, (1) 89-96.
10.2174/1568009617666170203162556
Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M(2017). The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treatment Reviews vol. 61, 53-60.
10.1016/j.ctrv.2017.09.011
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S et al.(2017). Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell vol. 171, (6) 1259-1271.e11.
10.1016/j.cell.2017.10.001
De Laurentiis M, Montemurro F, Bachelot T, Martin M, Barrios C, Kaufman B, Schmid P, Alba E et al.(2017). The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer: the EarLEE adjuvant clinical trials program. Annals of oncology : official journal of the European Society for Medical Oncology vol. 28,
10.1093/annonc/mdx424.044
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. (2017). A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. ANNALS OF ONCOLOGY. Conference: ESMO vol. 28,
Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. (2017). Association of PD-L2 expression in human tumors with atezolizumab activity. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 134-134.
Martin Jimenez M, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. (2017). EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC). ANNALS OF ONCOLOGY. vol. 28,
Schmid P, Cortes Castan J, Bergh J, Pusztai L, Denkert C, Verma S, McArthur HL, Zhao J et al. (2017). KEYNOTE-522: Phase III study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo 1 chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). ANNALS OF ONCOLOGY. vol. 28,
Loi S, Adams S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. (2017). Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. ANNALS OF ONCOLOGY. vol. 28,
Beddowes E, Spicer J, Chan PY, Khadeir R, Garcia Corbacho J, Repana D, Steele JP, Schmid P et al.(2017). Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers. Journal of Clinical Oncology vol. 35, (16) 1778-1785.
10.1200/JCO.2016.71.3230
Schmid P, Forster MD, Summers YJ, Good J, Sarker S-J, Lim L, Mousa K, Middleton GW (2017). A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results. JOURNAL OF CLINICAL ONCOLOGY. Conference: ESMO vol. 35,
10.1200/JCO.2017.35.15_suppl.2548
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al.(2017). Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases vol. 64, (10) 1413-1421.
10.1093/cid/cix167
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S et al.(2017). Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). Journal of Clinical Oncology vol. 35, (14) 1506-1514.
10.1200/JCO.2016.69.7391
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA (2017). Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial. TRIALS. Conference: ICTMC/SCT 2017 vol. 18,
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50803
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA et al.(2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature vol. 545, (7655) 446-451.
10.1038/nature22364
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R et al.(2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity vol. 46, (4) 577-586.
10.1016/j.immuni.2017.03.013
Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P (2017). CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy. CANCER RESEARCH. vol. 77,
10.1158/1538-7445.SABCS16-P3-03-12
Lopez-Miranda E, Gavila J, Pernas S, Saura C, Oliveira M, Serra V, Schmid P, Lord S et al. (2017). PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007). CANCER RESEARCH. vol. 77,
10.1158/1538-7445.SABCS16-OT1-01-06
Schmid P, Pinder SE, Purushotham A, Thompson AM(2017). Reply to R.F. Sweis et al. Journal of Clinical Oncology vol. 35, (2) 261-262.
10.1200/JCO.2016.69.8019
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al.(2017). Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA oncology vol. 3, (1) 58-66.
10.1001/jamaoncol.2016.3049
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al.(2017). Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial. JAMA Oncology vol. 3, (1) E1-E9.
10.100l/jamaoncd.2016.3049
Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P(2017). Nivolumab in HIV-related non-small-cell lung cancer. Annals of Oncology vol. 28, (11)
10.1093/annonc/mdx321
Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P(2016). Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study. Clinical Breast Cancer vol. 16, (6) 514-519.
10.1016/j.clbc.2016.06.001
Mok T, Schmid P, Jr DCG, Syrigos K, Martin C, Yamamoto N, Aren O, Arrieta O et al. (2016). Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE. ANNALS OF ONCOLOGY. vol. 27,
Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. (2016). IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC. ANNALS OF ONCOLOGY. vol. 27,
Ma BBY, Rudin CM, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor VM et al. (2016). Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. ANNALS OF ONCOLOGY. vol. 27,
Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, He Y, Bagley RG et al. (2016). METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology. vol. 27,
10.1093/annonc/mdw365.88
Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK et al.(2016). Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Communications vol. 7, (1)
10.1038/ncomms11579
Bouchekioua-Bouzaghou K, Lenihan C, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P (2016). Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.AM2016-2819
Komulainen E, Shia A, Bansal J, Cavicchioli F, O'Leary K, Foster J, Schmid P (2016). Inhibition of heat shock protein 27 (Hsp27) expression by apatorsen as a therapeutic strategy in breast cancer. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.AM2016-3759
Lenihan C, Cavicchioli F, O'Leary K, Shia A, Schmid P (2016). The role of VAV-interacting Kruppel-like factor (VIK) in resistance to palbociclib in estrogen receptor-positive breast cancer. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.AM2016-2110
Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al.(2016). Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology vol. 34, (17) 1987-1994.
10.1200/JCO.2015.63.9179
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14490
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B et al.(2016). Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology vol. 17, (6) 811-821.
10.1016/S1470-2045(16)00106-6
Schmid P, Wheatley DA, Thompson AM, Roy P, Bundred NJ, Purushotham AD, McIntosh S, Kummel S et al. (2016). ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 34,
10.1200/JCO.2016.34.15_suppl.TPS619
Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K et al.(2016). 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. Journal of Thoracic Oncology vol. 11, (4) S140-S141.
10.1016/S1556-0864(16)30301-X
Cortes J, Martinez Janesz N, Sablin MP, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart MP et al. (2016). Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part. EUROPEAN JOURNAL OF CANCER. vol. 57, S112-S112.
Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L et al.(2016). Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. Breast vol. 26, 149-150.
10.1016/j.breast.2015.12.011
Schmid P, Wheatley D, Baird R, Chan S, Abraham J, Tutt A, Kristeleit H, Patel G et al. (2016). A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC) (NCT02423603). CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-OT1-03-13
Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E (2016). A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC). CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-OT1-01-06
Lenihan C, Bouchekioua-Bouzaghou K, Shia A, Wilkes E, Casado-Izguierdo P, Cutillas P, Schmid P (2016). Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-P3-06-02
Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. (2016). High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI). CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-PD6-03
Schmid P, Ferreira M, Dubey S, Zaiss M, Harper-Wynne C, Makris A, Brown V, Kristeleit H et al. (2016). MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-OT1-03-12
Schmid P, Pinder SE, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R et al. (2016). Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study). CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-P5-13-01
Mok T, Schmid P, Aren O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. (2015). Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE. ANNALS OF ONCOLOGY. vol. 26, 147-147.
Schmid P, Muthukumar D, Blackhall F, Lester J, Khan S, Illsley MC, Adams J, Baijal S et al.(2015). Addition of Hsp27 Inhibitor Apatorsen to First-Line Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer: Design of the Cedar (TM) Trial. JOURNAL OF THORACIC ONCOLOGY vol. 10, (9) S664-S664.
O Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al.(2015). Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. British Journal of Cancer
10.1038/bjc.2015.302
Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel EE, Chaft J et al. (2015). NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents distinct cancer subtypes. EUROPEAN JOURNAL OF CANCER. vol. 51, S602-S602.
10.1016/S0959-8049(16)31661-6
Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR et al.(2015). Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Annals of Oncology vol. 26, (9) 1904-1910.
10.1093/annonc/mdv263
Schmid P, Muthukumar D, Blackhall FH, Lester JF, Khan S, Illsley M, Adams J, Garcia-Alonso A et al. (2015). Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. (2015). Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. (2015). Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.tps2612
Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. (2015). Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study). CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-S2-03
Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. (2015). Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC). ANNALS OF ONCOLOGY. vol. 26,
10.1093/annonc/mdv115.1
Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al.(2015). Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Annals of Oncology vol. 26,
10.1093/annonc/mdv115.01
Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S et al. (2015). The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER plus , aromatase inhibitor ( AI) resistant advanced or metastatic breast cancer - Part I results. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-S2-02
O'Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al.(2015). Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. British Journal of Cancer vol. 113, (6) 970-978.
10.1038/bjc.2015.302
Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, Lüftner D(2015). Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. Journal of Neuroimmunology vol. 287, 88-92.
10.1016/j.jneuroim.2015.08.012
Neumayr G, Fries D, Mittermayer M, Humpeler E, Klingler A, Schobersberger W, Spiesberger R, Pokan R et al.(2014). Effects of hiking at moderate and low altitude on cardiovascular parameters in male patients with metabolic syndrome: Austrian Moderate Altitude Study. Wilderness & environmental medicine vol. 25, (3) 329-334.
10.1016/j.wem.2014.01.003
Meisenberg C, Ward SE, Schmid P, El-Khamisy SF(2014). TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan. J Cancer Sci Ther vol. 6, (7) 258-267.
10.4172/1948-5956.1000280
Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P(2014). A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Medicine vol. 12, (1)
10.1186/1741-7015-12-93
Dizdarevic S, McCready R, Turner JFC, Bagley MC, Blower P, Schmid P, Flux G, Hall A et al.(2014). Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41, (6) 1255-1256.
10.1007/s00259-014-2725-7
Traina TA, O'Shaughnessy J, Kelly CM, Schwartzberg LS, Gucalp A, Peterson AC, Tudor IC, Blaney ME et al. (2014). A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.tps1144
Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Löbner C, Jung S, Böhm G et al.(2014). Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets. PLoS ONE vol. 9, (3)
10.1371/journal.pone.0090948
Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N et al.(2014). A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ANNALS OF ONCOLOGY vol. 25, (2) 505-511.
10.1093/annonc/mdt535
Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H(2014). Practice guidelines for exercise testing. Atemwegs- und Lungenkrankheiten vol. 40, (6) 223-244.
10.5414/ATX0947
Denne L, Shia A, Komulainen E, Haley V, Lenihan C, Cavicchioli F, O'Leary K, Schmid P(2013). The potent anti-androgen enzalutamide demonstrates broad anti-tumour activity across all androgen receptor-positive triple-negative breast cancer subtypes. CANCER RESEARCH vol. 73,
10.1158/0008-5472.SABCS13-P2-09-05
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K et al.(2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research vol. 15, (5)
10.1186/bcr3493
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson AM, Lackner M, Jones LJ et al. (2013). Sensitivity to glutamine deprivation is dependent on the interplay between epigenetic regulation of Glutamine synthetase (Glul) and induction of autophagy. EUROPEAN JOURNAL OF CANCER. vol. 49, S141-S141.
Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A et al.(2013). A phase i dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment vol. 140, (1) 73-82.
10.1007/s10549-013-2597-8
Cope S, Ouwens MJNM, Jansen JP, Schmid P(2013). Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: A network meta-analysis with parametric survival models. Value in Health vol. 16, (2) 403-417.
10.1016/j.jval.2012.10.019
Eder B, Hofmann P, Hödl R, Wonisch M, Schmid P, Pokan R(2013). Cardiac rehabilitation effective in elderly patients?. Journal fur Kardiologie vol. 20, (9-10) 262-268.
Aad G, Abajyan T, Abbott B, Abdallah J, Khalek SA, Abdelalim AA, Abdinov O, Aben R et al.(2012). A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider. SCIENCE vol. 338, (6114) 1576-1582.
10.1126/science.1232005
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook TR, Thompson AM, Lackner M, Lo NC et al. (2012). Epigenetic silencing of glutamine synthetase (Glul) defines glutamine depletion therapy. CANCER RESEARCH. vol. 72,
10.1158/0008-5472.SABCS12-P4-06-10
Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E et al.(2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer vol. 78, (3) 239-244.
10.1016/j.lungcan.2012.08.017
Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D et al.(2012). The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. British Journal of Cancer vol. 107, (8) 1423-1432.
10.1038/bjc.2012.380
Aad G, Abajyan T, Abbott B, Abdallah J, Abdel Khalek S, Abdelalim AA, Abdinov O, Aben R et al.(2012). Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC. Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics vol. 716, (1) 1-29.
10.1016/j.physletb.2012.08.020
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7380
Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. (2012). EPIGENETIC SILENCING OF ARGININO-SUCCINATE SYNTHASE (ASS1) DEFINES ARGININE DEPLETION THERAPY AS A NOVEL TREATMENT STRATEGY FOR BREAST CANCER. ANNALS OF ONCOLOGY. vol. 23, 532-533.
O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. (2012). IDENTIFICATION OF ENDOGLIN (CD105) AS AN EPIGENETICALLY REGULATED CANDIDATE TUMOUR SUPPRESSOR GENE IN LUNG CANCER. ANNALS OF ONCOLOGY. vol. 23, 73-74.
Wonisch M, Marko C, Niebauer J, Pokan R, Schmid P, Wiesinger E(2012). Resistance training for patients with cardiovascular diseases. Wiener Klinische Wochenschrift vol. 124, (9-10) 326-333.
10.1007/s00508-012-0170-9
Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Niebauer J, Sinzinger H, Schmid P(2012). Discontinuation of combined resistance-endurance training increases cardiovascular risk factors. International Journal of Cardiology vol. 156, (2) 229-231.
10.1016/j.ijcard.2012.01.040
Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Wur¿schmidt F, Petry KU, Kimmig R et al.(2011). Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NOGGO-AGO intergroup study. Journal of Clinical Oncology vol. 29, (28) 3791-3797.
10.1200/JCO.2010.30.4899
Berent R, Von Duvillard SP, Crouse SF, Sinzinger H, Green JS, Schmid P(2011). Resistance training dose response in combined endurance-resistance training in patients with cardiovascular disease: A randomized trial. Archives of Physical Medicine and Rehabilitation vol. 92, (10) 1527-1533.
10.1016/j.apmr.2011.04.021
Berent R, Auer J, Franklin B, Schmid P, Von Duvillard SP(2011). Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. American Journal of Cardiology vol. 108, (5) 644-650.
10.1016/j.amjcard.2011.04.011
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y et al.(2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet vol. 378, (9793) 771-784.
10.1016/S0140-6736(11)60993-8
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M et al.(2011). High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials. Journal of Clinical Oncology vol. 29, (24) 3224-3231.
10.1200/JCO.2010.32.5936
Eggeman H, Stöblen F, Thill M, Korlach S, Schmid P, Lüftner D, Elling D, Taran FA et al.(2011). Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes. Anticancer Research vol. 31, (8) 2617-2622.
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU et al.(2011). Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Research vol. 31, (8) 2589-2595.
Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al.(2011). Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res vol. 71, (9) 3317-3327.
10.1158/0008-5472.CAN-10-2048
White S, Harvey R, Mitchell H, Schmid P, Seckl M, Savage P(2011). Characterisation of transient benign hCG elevations in women following chemotherapy for GTT. Journal of Obstetrics and Gynaecology vol. 31, (2) 169-172.
10.3109/01443615.2010.536859
SCHMID-ARAYA J, Figueroa Hernandez D, Schmid PE, Drouot C(2011). Algivory in food webs of three temperate Andean rivers. Austral Ecology
10.1111/j.1442-9993.2011.02298.x
Berent R, Auer J, Schmid P, Krennmair G, Crouse SF, Green JS, Sinzinger H, Von Duvillard SP(2011). Periodontal and coronary heart disease in patients undergoing coronary angiography. Metabolism: Clinical and Experimental vol. 60, (1) 127-133.
10.1016/j.metabol.2009.12.016
Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, Lang IM, Marko C et al.(2011). Practical implementation of guidelines for lipid lowering. Journal fur Kardiologie vol. 18, (3-4) 96-99.
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al.(2010). Drift Time Measurement in the ATLAS Liquid Argon Electromagnetic Calorimeter using Cosmic Muons. EUR PHYS J C vol. 70, (3) 755-785.
10.1140/epjc/s10052-010-1403-6
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al.(2010). Readiness of the ATLAS liquid argon calorimeter for LHC collisions. EUR PHYS J C vol. 70, (3) 723-753.
10.1140/epjc/s10052-010-1354-y
Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D(2010). Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integrative Cancer Therapies vol. 9, (3) 270-275.
10.1177/1534735410370036
Oguogho A, Efthimiou Y, Iliopoulos J, Stomatopoulos J, Ahmadzadehfar H, Schmid P, Steinbrenner D, Sinzinger H(2010). Prickly pear changes <sup>111</sup>indium?LDL and <sup>111</sup>indium-HDL platelet binding correlating to improvement of platelet function in hypercholesterolemia. Journal of the Professional Association for Cactus Development vol. 12, 67-79.
Blackhall FH, Obrien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N(2010). A phase i study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. Journal of Thoracic Oncology vol. 5, (8) 1285-1288.
10.1097/JTO.0b013e3181e3a2d1
Berent R, Auer J, Von Duvillard SP, Sinzinger H, Schmid P(2010). Complications during exercise testing. Herz vol. 35, (4) 267-272.
10.1007/s00059-011-3449-0
Schmid PE, Schmid-Araya JM(2010). Scale-dependent relations between bacteria, organic matter and invertebrates in a headwater stream. FUND APPL LIMNOL vol. 176, (4) 365-375.
10.1127/1863-9135/2010/0176-0365
McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ(2010). The management and outcome of women with post-hydatidiform mole low-risk gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l<sup>-1</sup>. British Journal of Cancer vol. 102, (5) 810-814.
10.1038/sj.bjc.6605529
Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G et al.(2010). Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: Final results of a randomised phase III trial. Annals of Oncology vol. 21, (7) 1430-1435.
10.1093/annonc/mdp585
Berent R, Auer J, Von Duvillard S, Sinzinger H, Steinbrenner D, Schmid P(2010). Acute myocardial infarction with ST segment elevation in inferior and anterior leads: Right ventricular infarction. BMJ Case Reports
10.1136/bcr.03.2009.1700
Berent R, von Duvillard SP, Auer J, Sinzinger H, Schmid P(2010). Lack of supervision after residential cardiac rehabilitation increases cardiovascular risk factors. European Journal of Preventive Cardiology vol. 17, (3) 296-302.
10.1097/HJR.0b013e3283318874
Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, Robertson J, Swain S et al.(2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute - Monographs vol. 41, 162-177.
10.1093/jncimonographs/lgq039
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ et al.(2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology vol. 20, (11) 1771-1785.
10.1093/annonc/mdp261
Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H et al.(2009). Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Annals of Oncology vol. 21, (3) 633-639.
10.1093/annonc/mdp491
Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al.(2009). Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer vol. 125, (6) 1454-1463.
10.1002/ijc.24546
Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, Lindsay I, Wells M et al.(2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. The Lancet vol. 374, (9683) 48-55.
10.1016/S0140-6736(09)60618-8
Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, Heinrich G, Steck T et al.(2009). Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: Final results of a phase II trial. Cancer Chemotherapy and Pharmacology vol. 64, (2) 401-406.
10.1007/s00280-008-0887-3
Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer JU, Sehouli J et al.(2009). Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Research vol. 29, (2) 641-645.
Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Sinzinger H, Schmid P(2009). Short-term residential cardiac rehabilitation reduces B-type natriuretic peptide. European Journal of Cardiovascular Prevention and Rehabilitation vol. 16, (5) 603-608.
10.1097/HJR.0b013e32832d7ca8
Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H(2008). Practice guidelines for exercise testing. Journal fur Kardiologie vol. 15, (SUPPL. A) 3-17.
Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ(2008). Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/ etoposide (TP/TE). Annals of Oncology vol. 19, (9) 1578-1583.
10.1093/annonc/mdn181
Harvey RA, Pursglove HD, Schmid P, Savage PM, Mitchell HDC, Seckl MJ(2008). Human chorionic gonadotropin free β-subunit measurement as a marker of placental site trophoblastic tumors. Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53, (8) 643-648.
Lim AKP, Patel D, Patel N, Hawtin K, Dayal L, Schmid P, Savage P, Seckl MJ(2008). Pelvic imaging in gestational trophoblastic neoplasia. Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53, (8) 575-578.
Aad G, Abat E, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi BA, Abolins M et al.(2008). The ATLAS Experiment at the CERN Large Hadron Collider. J INSTRUM vol. 3, Article S08003,
10.1088/1748-0221/3/08/S08003
Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J et al.(2008). A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Annals of Oncology vol. 19, (5) 871-876.
10.1093/annonc/mdm569
Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ(2008). Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy. Cancer Chemotherapy and Pharmacology vol. 61, (2) 347-348.
10.1007/s00280-007-0590-9
Schmid P(2007). Bisphosphonate for the treatment of tumor induced in bone changes. Onkologe vol. 13, (7) 609-618.
10.1007/s00761-007-1209-9
Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS et al.(2007). Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Annals of Oncology vol. 18, (7) 1177-1184.
10.1093/annonc/mdm091
Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L et al.(2007). Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study. Journal of Clinical Oncology vol. 25, (18) 2509-2515.
10.1200/JCO.2006.08.8534
Schmid P(2007). High-dose chemotherapy for breast cancer. Onkologe vol. 13, (5) 409-424.
10.1007/s00761-006-1090-y
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al.(2007). A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. British Journal of Cancer vol. 96, (5) 732-737.
10.1038/sj.bjc.6603608
Kümmel S, Rezai M, Kimmig R, Schmid P(2007). Dose-dense chemotherapy for primary breast cancer. Current Opinion in Obstetrics and Gynecology vol. 19, (1) 75-81.
10.1097/GCO.0b013e328011f99a
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J et al.(2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology vol. 18, (2) 215-225.
10.1093/annonc/mdl155
Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R et al.(2007). Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes. International Journal of Biological Markers vol. 22, (3) 186-193.
10.5301/JBM.2008.1561
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.(2006). Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416). British Journal of Cancer vol. 95, (12)
10.1038/sj.bjc.6603536
Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K et al.(2006). Biomarkers of depression in cancer patients. Cancer vol. 107, (11) 2723-2729.
10.1002/cncr.22294
Possinger K, Schmid P(2006). Chemotherapy for metastatic breast cancer. Zentralblatt fur Gynakologie vol. 128, (6) 318-326.
10.1055/s-2006-921561
Schmid P(2006). Mechanism of action and application possibilities: Adjuvant hormonal therapy of breast carcinoma. Best Practice Onkologie vol. 1, (1) 42-57.
10.1007/s11654-006-0003-2
Powles T, Young A, Sammit A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.(2006). The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. British Journal of Cancer vol. 95, (9) 1145-1147.
10.1038/sj.bjc.6603416
Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Frank J et al. (2006). Value of whole body <sup>18</sup>FDG-PET to identify the active site of gestational trophoblastic neoplasia. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. vol. 51, 879-887.
Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES et al.(2006). Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment. Journal of Clinical Oncology vol. 24, (30) 4862-4866.
10.1200/JCO.2006.06.2489
Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M et al.(2006). Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. British Journal of Sports Medicine vol. 40, (9) 773-778.
10.1136/bjsm.2006.027250
Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M(2006). The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy. J Clin Oncol vol. 24, (18_suppl)
Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G et al. (2006). Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Research. vol. 26, 1719-1726.
Kümmel S, Elling D, Jeschke S, Schmid P, Thomas A (2006). Chemotherapy treatment options for elderly women with breast cancer. Anticancer Research. vol. 26, 1673-1676.
Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M et al.(2005). Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: Results of a randomized trial. Journal of Clinical Oncology vol. 23, (3) 432-440.
10.1200/JCO.2005.06.072
Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S et al.(2005). Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial. Annals of Oncology vol. 16, (10) 1624-1631.
10.1093/annonc/mdi321
Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Possinger K et al.(2005). Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: A phase II study. Journal of Cancer Research and Clinical Oncology vol. 131, (9) 568-574.
10.1007/s00432-005-0675-y
Schmid P, Flath B, Akrivakis K, Heilmann V, Mergenthaler HG, Sezer O, Kreienberg R, Possinger K(2005). Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study. Investigational New Drugs vol. 23, (4) 349-356.
10.1007/s10637-005-1443-1
Schmid P, Possinger K(2005). Gemcitabin (Gemzar). Gynakologische Praxis vol. 29, (2) 351-358.
Schmid P, Possinger K(2005). Gemcitabine (Gemzar). Internistische Praxis vol. 45, (2) 415-422.
Schmid P, Possinger K(2005). Gemcitabin (Gemzar). Padiatrische Praxis vol. 66, (3) 521-528.
Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K et al.(2005). Proteasome: An emerging target for cancer therapy. Anti-Cancer Drugs vol. 16, (5) 475-481.
10.1097/00001813-200506000-00002
Schmid P, Possinger K(2005). Gemcitabin (Gemzar). Chirurgische Praxis vol. 64, (2) 351-358.
Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K(2005). Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study. Investigational New Drugs vol. 23, (2) 139-146.
10.1007/s10637-005-5859-4
Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU et al.(2005). Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: Results of a phase I trial. Anti-Cancer Drugs vol. 16, (1) 21-29.
10.1097/00001813-200501000-00003
Pokan R, Von Duvillard SP, Ludwig J, Rohrer A, Hofmann P, Wonisch M, Smekal G, Schmid P et al.(2004). Effect of high-volume and -intensity endurance training in heart transplant recipients. Medicine and Science in Sports and Exercise vol. 36, (12) 2011-2016.
10.1249/01.MSS.0000147630.71210.06
Untch M, Kahlert S, Kosse V, Bondar G, Kienle E, Maubach L, Hillger H, Schmid P et al.(2004). Leuprorelinacetate as a 3 month depot has the same efficacy as CMF in the adjuvant therapy of pre-perimenopausal, node positive breast cancer patients with positive receptor status - The TABLE study. Geburtshilfe und Frauenheilkunde vol. 64, (12) 1316-1323.
10.1055/s-2004-830329
Dieing A, Schulz CO, Schmid P, Roever AC, Lehenbauer-Dehm S, Jehn C, Flath B, Possinger K(2004). Orbital metastases in breast cancer: Report of two cases and review of the literature. Journal of Cancer Research and Clinical Oncology vol. 130, (12) 745-748.
10.1007/s00432-004-0606-3
Schmid P, Helmreich G, Gradauer L, Stowasser G, Bronnenmayer J, Pokan R(2004). Are there non responders to exercise therapy after myocardial infarction?. Journal fur Kardiologie vol. 11, (11) 453-457.
Pokan R, Hofmann P, Wonisch M, Smekal G, Bachl N, Mayr K, Benzer W, Schmid P(2004). Performance diagnostic and target training heart rate in cardiac rehabilitation. Journal fur Kardiologie vol. 11, (11) 446-452.
Höfer S, Benzer W, Brandt D, Laimer H, Schmid P, Bernardo A, Oldridge NB(2004). MacNew Heart Disease Questionnaire after myocardial infarction: The German version. Zeitschrift fur Klinische Psychologie und Psychotherapie vol. 33, (4) 270-280.
10.1026/1616-3443.33.4.270
Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T et al.(2004). Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: Final results of a multicenter phase II study. Journal of Cancer Research and Clinical Oncology vol. 130, (11) 657-663.
10.1007/s00432-004-0599-y
Schmid P, Helmreich G, Gradauer L, Schmid F(2004). Percutaneous transradial artery approach for coronary diagnostics and PCI. Journal fur Kardiologie vol. 11, (9) 359-362.
Pokan R, Wonisch M, Schmid P(2004). Changes in the athlete's heart in the ECG. Internistische Praxis vol. 44, (1) 79-88.
Schmid P, Schmid F, Smekal G, Pokan R(2003). Physical Activity and Primary Prevention. Journal fur Kardiologie vol. 10, (12) 548-553.
Schmid P, Possinger K (2003). Bisphosphonates in metastatic breast cancer. Breast Cancer Research and Treatment. vol. 81,
Beslija S, Bonneterre J, Burstein HJ, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W et al. (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment. vol. 81,
Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K(2003). Upregulation of HER-2/neu by ovarian ablation: Results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Research and Treatment vol. 80, (3) 245-255.
10.1023/A:1024911625339
Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O(2003). Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. British Journal of Cancer vol. 88, (9) 1406-1410.
10.1038/sj.bjc.6600935
Schobersberger W, Schmid P, Lechleitner M, von Duvillard SP, Hörtnagl H, Gunga HC, Klingler A, Fries D et al.(2003). Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. European Journal of Applied Physiology vol. 88, (6) 506-514.
10.1007/s00421-002-0736-8
Schmid P, Possinger K (2003). Which treatment when?. Breast Cancer Research and Treatment. vol. 81,
10.1023/a:1026300302967
Schmid P, Possinger K(2002). Interactions of antioestrogens and aromatase inhibitors. FORUM - Trends in Experimental and Clinical Medicine vol. 12, (1) 45-59.
Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K(2002). Prediction of response to hormonal treatment in metastatic breast cancer. Oncology vol. 63, (4) 309-316.
10.1159/000066224
Schmid P, Possinger K(2002). High-dose chemotherapy in breast cancer. Medizinische Klinik vol. 97, (11) 677-686.
10.1007/s00063-002-1211-3
Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler HG, Huhn D et al.(2002). The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas. Anti-Cancer Drugs vol. 13, (9) 907-913.
10.1097/00001813-200210000-00002
Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E et al.(2002). Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Research vol. 22, (4) 2325-2332.
Schmid P, Possinger K(2002). High-dose chemotherapy in high-risk primary breast cancer. Onkologie vol. 25, (2) 112-120.
10.1159/000055220
Schmid P, Possinger K(2002). Systemic therapy in breast cancer - Adjuvant and neo-adjuvant treatment: Update situation and update studies. Viszeralchirurgie vol. 37, (2) 137-149.
10.1055/s-2002-25170
Schmid P, Possinger K(2002). Adjuvant and neoadjuvant systemic therapy of breast cancer. Internist vol. 43, (3) 341-353.
10.1007/s00108-001-0523-3
Pokan R, Hofmann P, Smekal G, Wonisch M, Bachl N, Schmid P(2002). Performance testing for regulating training in exercise therapy of cardiovascular disease. Internistische Praxis vol. 42, (4) 797-806.
Schmid P, Sezer O, Possinger K(2001). Bisphosphonates in oncology. Pharmazie in Unserer Zeit vol. 30, (6) 519-528.
10.1002/1615-1003(200111)30:6<519::AID-PAUZ519>3.0.CO;2-D
Schmid P, Fritz J, Possinger K(2001). Treatment options for metastatic breast cancer. Internistische Praxis vol. 41, (2) 319-332.
Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K(2001). Achievement of complete remission in refractory Hodgkin's disease with prolonged infussion of gemcitabine. Investigational New Drugs vol. 19, (1) 101-104.
10.1023/A:1006478702342
Sinzinger H, Hoppichler F, Kritz H, Laimer H, Schmid P, Silberbauer K, Toplak H(2001). HDL-2000 - Ein konsensus. Wiener Klinische Wochenschrift vol. 113, (5-6) 212-214.
Grosse Y, Schmid P, Possinger K(2001). Bisphosphonates in the treatment of breast cancer. Prevention and adjuvant therapy. Tagliche Praxis vol. 42, (4) 727-734.
Pokan R, Pelikan J, Retzer H, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Fruhwald FM et al.(2001). Leistungsfähigkeit und herzfrequenz von patienten mit KHK im MAXLASS und deren zusammenhang mit dem herzfrequenzverhalten und der myokardialen funktion unter belastung im stufentest. Deutsche Zeitschrift fur Sportmedizin vol. 52, (7-8)
Schmid P, Possinger K(2001). Liposomal anthracyclines for improved cardiac tolerability. Breast vol. 10, (SUPPL. 2) 22-27.
10.1016/S0960-9776(01)80004-7
Schmid P(2001). Stellenwert der Bewegungstherapie in der Primär- und Sekundärprävention der KHK. Deutsche Zeitschrift fur Sportmedizin vol. 52, (7-8)
Lueftner DI, Schmid P, Kienle E, Possinger K(2001). Upregulation of Her-2/neu under chemical castration: Serum results of a randomized trial comparing leuprorelin acetate to CMF for adjuvant therapy of nodal-positive breast cancer. Breast Cancer Research and Treatment vol. 69, (3)
Sezer O, Eucker J, Jakob C, Schmid P, Possinger K(2000). Prolonged infusion of gemcitabine in refractory hodgkin's disease. Blood vol. 96, (11 PART II)
Possinger K, Schmid P (2000). Therapeutic possibilities in breast carcinoma. Onkologe. vol. 6,
10.1007/s007610070002
Sezer O, Langelotz C, Blohmer JU, Schmid P, Akrivakis K, Possinger K(2000). Detection of HMGI-C in the peripheral blood of breast cancer patients. European Journal of Cancer vol. 36, (15) 1944-1948.
10.1016/S0959-8049(00)00199-4
Schmid PE, Tokeshi M, Schmid-Araya JM(2000). Relation between population density and body size in stream communities. Science vol. 289, (5484) 1557-1560.
10.1126/science.289.5484.1557
Schmid P, Possinger K(2000). Advanced breast cancer. Palliative measures are becoming ever more tolerable. MMW-Fortschritte der Medizin vol. 142, (35) 22-24.
Possinger K, Schmid P(2000). New drugs for the treatment of breast cancer. Onkologe vol. 6, (5) 392-409.
10.1007/s007610070101
Böttner A, Pirro F, Schmid P, Traeder W, Weiskopf S, Weiss H, Zschiesche E(2000). [Guidelines for planning studies to determine the resistance of infectious agents of veterinary relevance]. Berl Munch Tierarztl Wochenschr vol. 113, (7-8) 299-305.
Sinzinger H, Chehne F, Schmid P, Kritz H(2000). Plasma homocysteine is not altered during simvastatin-therapy. Wiener Klinische Wochenschrift vol. 112, (12) 540-543.
Pokan R, Von Duvillard SP, Hofmann P, Smekal G, Fruhwald FM, Gasser R, Tschan H, Baron R et al.(2000). Change in left atrial and ventricular dimensions during and immediately after exercise. Medicine and Science in Sports and Exercise vol. 32, (10) 1713-1718.
10.1097/00005768-200010000-00009
Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Stuschke M, Schweigert M, Siebert G et al.(2000). Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy. Journal of Cancer Research and Clinical Oncology vol. 126, (6) 352-356.
10.1007/s004320050355
Sezer O, Eucker J, Schmid P, Possinger K(2000). New therapeutic approaches in primary systemic AL amyloidosis. Annals of Hematology vol. 79, (1) 1-6.
10.1007/s002770050001
Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K(1999). Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-Cancer Drugs vol. 10, (7) 625-631.
10.1097/00001813-199908000-00001
Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler HG, Possinger K(1999). Eosinophila during fludarabine treatment of chronic lymphocytic leukemia. Annals of Hematology vol. 78, (10) 475-477.
10.1007/s002770050602
Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K(1999). Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study. Anti-Cancer Drugs vol. 10, (6) 525-531.
10.1097/00001813-199907000-00003
Sinzinger H, Schmid P, O'Grady J(1999). Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [3]. Atherosclerosis vol. 143, (2) 459-460.
10.1016/S0021-9150(98)00310-4
Helmreich G, Gradauer L, Schmid P(1999). Duration and complications in diagnostic coronary angiography via the radial artery. Journal fur Kardiologie vol. 6, (10-11) 545-549.
Schmid P, Helmreich G, Gradauer L(1999). Methods for diagnostic coronary angiography via the radial artery. Journal fur Kardiologie vol. 6, (10-11) 538-542.
Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H et al.(1999). Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplantation vol. 23, (9) 967-969.
10.1038/sj.bmt.1701765
Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Hogler R, Tschan H, Baron R, Schmid P et al.(1999). The heart rate turn point reliability and methodological aspects. Medicine and Science in Sports and Exercise vol. 31, (6) 903-907.
10.1097/00005768-199906000-00021
Sezer O, Schmid P, Mergenthaler HG, Beinert T, Possinger K(1999). Use of bisphosphonates in therapy and prophylaxis of cancer-induced bone diseases. Onkologie vol. 22, (5) 400-404.
10.1159/000026989
Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Smekal G, Gasser R, Klein W, Eber B et al.(1998). The heart rate performance curve and left ventricular function during exercise in patients after myocardial infarction. Medicine and Science in Sports and Exercise vol. 30, (10) 1475-1480.
10.1097/00005768-199810000-00002
Pokan R, Hofmann P, Von Duvillard SP, Schumacher M, Gasser R, Zweiker R, Fruhwald FM, Eber B et al.(1998). Parasympathetic receptor blockade and the heart rate performance curve. Medicine and Science in Sports and Exercise vol. 30, (2) 229-233.
10.1097/00005768-199802000-00009
Hofmann P, Pokan R, Von Duvillard SP, Schmid P, Conconi F, Grazzi G, Casoni I, Borsetto C et al.(1997). The Conconi test (multiple letters) [2]. International Journal of Sports Medicine vol. 18, (5) 397-399.
10.1055/s-2007-972654
Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Schumacher M, Fruhwald FM, Zweiker R, Eber B et al.(1997). Left ventricular function in response to the transition from aerobic to anaerobic metabolism. Medicine and Science in Sports and Exercise vol. 29, (8) 1040-1047.
10.1097/00005768-199708000-00009
Hofmann P, Pokan R, Bachl N, Schmid P(1997). A short communication regarding the article by M. Kara et al. "Determination of the heart rate deflection point by the Dmax method." (J Sports Med Phys Fitness 1996;36(1):31-4). The Journal of sports medicine and physical fitness vol. 37, (2) 151-155.
O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H(1997). Effect of isradipine on in-vivo platelet function. Thrombosis Research vol. 86, (5) 363-371.
10.1016/S0049-3848(97)00081-9
Hofmann P, Pokan R, Von Duvillard SP, Seibert FJ, Zweiker R, Schmid P(1997). Heart rate performance curve during incremental cycle ergometer exercise in healthy young male subjects. Medicine and Science in Sports and Exercise vol. 29, (6) 762-768.
10.1097/00005768-199706000-00005
Kritz H, Schmid P, Karanikas G, Rodrigues M, Sinzinger H(1997). Detection of early atherosclerotic lesions in the carotid artery: Experimental and preliminary human data. International Journal of Angiology vol. 6, (1) 24-29.
10.1007/BF01616229
Sinzinger H, Kritz H, Virgolini I, Schmid P, Rogatti W(1996). Prostaglandin E<inf>1</inf> increases binding of<sup>123</sup>l-low-density lipoprotein to the human liver in vivo. European Journal of Clinical Pharmacology vol. 49, (6) 515-520.
10.1007/s002280050059
Kritz H, Schmid P, Karanikas G, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H(1996). Passive smoking increases platelet thromboxane. International Journal of Angiology vol. 5, (3) 134-139.
10.1007/BF02043209
Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC(1996). Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer vol. 77, (10) 2109-2116.
10.1002/(SICI)1097-0142(19960515)77:10<2109::AID-CNCR22>3.0.CO;2-Y
Benzer W, Schmid P, Maehr G, Drexel H(1996). Effects of intravenous magnesium chloride reverses left ventricular end-diastolic pressure in coronary artery disease. American Journal of Cardiology vol. 77, (8) 638-640.
10.1016/S0002-9149(97)89321-6
Schmid P, Karanikas G, Kritz H, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H(1996). Passive smoking and platelet thromboxane. Thrombosis Research vol. 81, (4) 451-460.
10.1016/0049-3848(96)00017-5
Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R et al.(1996). Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. European Journal of Cancer Part A vol. 32, (10) 1712-1718.
10.1016/0959-8049(96)00186-4
Kritz H, Schmid P, Keiler A, O'Grady J, Sinzinger H(1995). Isradipine increases vascular prostaglandin I<inf>2</inf>-formation while the thromboxane B<inf>2</inf>-synthesis is diminished. Thrombosis Research vol. 80, (6) 483-489.
10.1016/0049-3848(95)00203-0
Benzer W, Schmid P(1995). Rehabilitation after myocardial infarct--a multidisciplinary responsibility. Wiener klinische Wochenschrift vol. 107, (24)
Kritz H, Schmid P, Sinzinger H(1995). Passive Smoking and Cardiovascular Risk. Archives of Internal Medicine vol. 155, (18) 1942-1948.
10.1001/archinte.1995.00430180034005
Pokan R, Hofmann P, Lehmann M, Leitner H, Eber B, Gasser R, Schwaberger G, Schmid P et al.(1995). Heart rate deflection related to lactate performance curve and plasma catecholamine response during incremental cycle ergometer exercise. European Journal of Applied Physiology and Occupational Physiology vol. 70, (2) 175-179.
10.1007/BF00361546
Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar BA(1994). Sleep disturbance and appetite loss after lovastatin. The Lancet vol. 343, (8903)
10.1016/S0140-6736(94)90094-9
Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H (1994). Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Pressure, Supplement. vol. 3, 75-80.
Pirich C, Fitscha P, Schmid P, Sinzinger H (1994). Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall. Blood Pressure, Supplement. vol. 3, 70-74.
Schmid P, Pirich C, Fitscha P, Pesau B, Virgolini I, Sinzinger H (1994). Isradipine increases platelet - Low-density lipoprotein binding: Evidence from ex-vivo studies in humans. Blood Pressure, Supplement. vol. 3, 65-69.
Sinzinger H, Schmid P, Pirich C, Virgolini I, Pesau B, Granegger S, O'Grady J(1992). Treatment of hypercholesterolaemia in children. The Lancet vol. 340, (8818) 548-549.
10.1016/0140-6736(92)91745-T
Pirich C, Schmid P, Pidlich J, Sinzinger H(1992). Cholesterol lowering by Anticholest® - a high-fiber guar-pectin drink. Wiener Klinische Wochenschrift vol. 104, (11) 314-316.
Return to top